BTIG analyst Thomas Shrader downgraded Sigilon Therapeutics (SGTX) to Neutral from Buy after Eli Lilly (LLY) agreed to acquire all outstanding shares at a cash price of $14.92 per share, totaling about $35M, along with one non-tradeable contingent value right, or CVR, per share, via which the holder may be entitled to receive up to an additional $111.64 per share in cash. The maximum deal price is in line with what Vertex (VRTX) paid for Viacyte, which BTIG calls “a company with much less compelling technology.” Lilly and Sigilon’s key programs in Diabetes are “very collaborative,” so counter offers seem unlikely, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGTX:
- Sigilon Jumps Over 7x on Acquisition by Eli Lilly
- Eli Lilly to acquire Sigilon Therapeutics for $14.92 per share in cash
- Lilly to Acquire Sigilon Therapeutics
- Sigilon Announces Reverse Stock Split of Common Stock
- Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights